Saltar al contenido
Merck

Increased cardiovascular risk in patients with rheumatoid arthritis: an overview.

Acta cardiologica (2014-05-03)
Daisy Puttevils, Philip De Vusser, Piet Geusens, Jo Dens
RESUMEN

Patients with established rheumatoid arthritis (RA) have a higher cardiovascular morbidity and mortality in comparison with the general population. It is considered to be an independent risk factor for cardiovascular disease. The purpose of this article is to describe the mechanisms responsible for accelerated atherogenesis in RA patients and to give an overview of the effects of different RA therapies (methotrexate, TNF antagonists and other biologicals).

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Metotrexato hydrate, ≥98% (HPLC), powder
Sigma-Aldrich
Metotrexato hydrate, powder, BioReagent, suitable for cell culture, ≥98% (HPLC)
Sigma-Aldrich
Metotrexato hydrate, meets USP testing specifications
SAFC
Methotrexate
Supelco
Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Methotrexate solution, 1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®
Methotrexate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Metotrexato hydrate, ≥99.0% (sum of enantiomers, HPLC)
Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard
Methotrexate for system suitability, European Pharmacopoeia (EP) Reference Standard